Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party.

Autor: Tettero JM; Department of Hematology, Amsterdam UMC, Location VUmc, Amsterdam, The Netherlands., Freeman S; Department of Clinical Immunology, Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, United Kingdom., Buecklein V; Department of Medicine III, University Hospital, LMU Munich, Germany., Venditti A; Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy., Maurillo L; Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy., Kern W; MLL Munich Leukemia Laboratory, Munich, Germany., Walter RB; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., Wood BL; Department of Pathology and Laboratory Medicine, Childrens Hospital Los Angeles, California, USA., Roumier C; Laboratory of Hematology, CHU Lille, France., Philippé J; Department of Laboratory Medicine, Ghent University Hospital, Ghent, Belgium., Denys B; Department of Laboratory Medicine, Ghent University Hospital, Ghent, Belgium., Jorgensen JL; Department of Hematopathology, UT MD Anderson Cancer Center, Houston, Texas, USA., Bene MC; Hematology Biology, Nantes University Hospital, Nantes, France., Lacombe F; Flow Cytometry Platform, University Hospital, Bordeaux, France., Plesa A; Laboratory of Hematology and Flow Cytometry, CHU Lyon-Sud Hospital, Hospices Civils de Lyon, France., Guzman ML; Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, USA., Wierzbowska A; Department of Hematology, Medical University of Lodz, Poland., Czyz A; Department of Hematology and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland., Ngai LL; Department of Hematology, Amsterdam UMC, Location VUmc, Amsterdam, The Netherlands., Schwarzer A; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Bachas C; Department of Hematology, Amsterdam UMC, Location VUmc, Amsterdam, The Netherlands., Cloos J; Department of Hematology, Amsterdam UMC, Location VUmc, Amsterdam, The Netherlands., Subklewe M; Department of Medicine III, University Hospital, LMU Munich, Germany., Fuering-Buske M; Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany., Buccisano F; Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Jazyk: angličtina
Zdroj: HemaSphere [Hemasphere] 2021 Dec 22; Vol. 6 (1), pp. e676. Date of Electronic Publication: 2021 Dec 22 (Print Publication: 2022).
DOI: 10.1097/HS9.0000000000000676
Abstrakt: Measurable residual disease (MRD) quantified by multiparameter flow cytometry (MFC) is a strong and independent prognostic factor in acute myeloid leukemia (AML). However, several technical factors may affect the final read-out of the assay. Experts from the MRD Working Party of the European LeukemiaNet evaluated which aspects are crucial for accurate MFC-MRD measurement. Here, we report on the agreement, obtained via a combination of a cross-sectional questionnaire, live discussions, and a Delphi poll. The recommendations consist of several key issues from bone marrow sampling to final laboratory reporting to ensure quality and reproducibility of results. Furthermore, the experiences were tested by comparing two 8-color MRD panels in multiple laboratories. The results presented here underscore the feasibility and the utility of a harmonized theoretical and practical MFC-MRD assessment and are a next step toward further harmonization.
(Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.)
Databáze: MEDLINE
Externí odkaz: